Padilla, O., Minns, H., Wei, H.-J., Webster-Carrion, A., Tazhibi, M., McQuillan, N., Zhang, X., Zhang, Z., Rabadan, R., Canoll, P., Szalontay, L., Pavisic, J., Garty, G., Zacharoulis, S., Vanpouille-Box, C., Menon, V., Olah, M., Wu, C.-C., & Gartrell, R. (2021). 91 Impact of ultra-fast ‘FLASH’ radiotherapy on single cell immunogenomics in diffuse intrinsic pontine glioma (DIPG). Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A100–A100. https://doi.org/10.1136/jitc-2021-sitc2021.091

Satish, T., Khan, S., Levin, M., Carvajal, R., & Yoon, A. J. (2021). Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission. Journal for ImmunoTherapy of Cancer, 9(10), e001219. https://doi.org/10.1136/jitc-2020-001219

Jan, C.-I., Huang, S.-W., Canoll, P., Bruce, J. N., Lin, Y.-C., Pan, C.-M., Lu, H.-M., Chiu, S.-C., & Cho, D.-Y. (2021). Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. Journal for ImmunoTherapy of Cancer, 9(10), e003050. https://doi.org/10.1136/jitc-2021-003050

de Klerk, L. K., Patel, A. K., Derks, S., Pectasides, E., Augustin, J., Uduman, M., Raman, N., Akarca, F. G., McCleary, N. J., Cleary, J. M., Rubinson, D. A., Clark, J. W., Fitzpatrick, B., Brais, L. K., Cavanaugh, M. E., Rode, A. J., Jean, M. G., Lizotte, P. H., Nazzaro, M. J., … Bass, A. J. (2021). Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. Journal for ImmunoTherapy of Cancer, 9(9), e002472. https://doi.org/10.1136/jitc-2021-002472

Leighl, N. B., Redman, M. W., Rizvi, N., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Wade, J. L., Irvin, W. J., Reddy, S. C., Crawford, J., Bradley, J. D., Stinchcombe, T. E., Ramalingam, S. S., Miao, J., Minichiello, K., Herbst, R. S., Papadimitrakopoulou, V. A., Kelly, K., & Gandara, D. R. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer, 9(8), e002973. https://doi.org/10.1136/jitc-2021-002973

Ager, C. R., Boda, A., Rajapakshe, K., Lea, S. T., Di Francesco, M. E., Jayaprakash, P., Slay, R. B., Morrow, B., Prasad, R., Dean, M. A., Duffy, C. R., Coarfa, C., Jones, P., & Curran, M. A. (2021). High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. Journal for ImmunoTherapy of Cancer, 9(8), e003246. https://doi.org/10.1136/jitc-2021-003246